Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 2 (3)

Trial Status

Active Not Recruiting1
Recruiting1
Not Yet Recruiting1
Unknown1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07703228Phase 2Active Not Recruiting

Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC

NCT07320586Phase 2Recruiting

Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

NCT07343453Phase 2Not Yet Recruiting

A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors

NCT04713059Unknown

Toripalimab Combined With Anlotinib for Patients With Advanced, Relapsed, or Refractory Gastric, or Esophagogastric Junction Cancer (EGJC)

Showing all 4 trials

Research Network

Activity Timeline